title: FK506 in the treatment of inflammatory skin disease: promises and perspectives.
abstract: The immunosuppressive macrolide drug FK506 is currently gaining increasing importance in dermatopharmacology. Here, Gunter Michel and colleagues summarize the current state of research into the molecular mechanisms responsible for the functional modulation of cell types other than T cells, particularly epidermal cells, by this drug.
authors.affiliation: Department of Dermatology, Heinrich-Heine-University, Dusseldorf, Germany. MICHELG@RZ.UNI-DUSSELDORF.DE
authors.forename: G
authors.initials: G
authors.lastname: Michel
authors.forename: L
authors.initials: L
authors.lastname: Kemeny
authors.forename: B
authors.initials: B
authors.lastname: Homey
authors.forename: T
authors.initials: T
authors.lastname: Ruzicka
mesh_terms: D000818:Animals; D003872:Dermatitis / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D012867:Skin / Q000187:drug effects; D013601:T-Lymphocytes / Q000187:drug effects; D016559:Tacrolimus / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus